Global Psoriasis Treatment Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2012-2016 and Forecast 2017-2023
Psoriasis is a chronic autoimmune disease characterized by abnormal growth of the skin cells. It forms skin patches above the skin and it is not contagious. Psoriasis skin patches are red and itchy. There are different types of psoriasis namely guttate psoriasis, plaque psoriasis, pustular psoriasis, erythrodermic psoriasis and inverse psoriasis. Plaque psoriasis is common and constitutes about 90% of psoriasis cases. The diagnosis of psoriasis is typically made by obtaining information from the physical examination of the skin, medical history, and relevant family health history. Psoriasis affects skin over the elbows, knees, and scalp and is often itchy. Although any area may be involved, it tends to be more common at sites of friction, scratching, or abrasion. Currently, there was no cure for psoriasis. However, treatment is focused on curing the symptoms. Treatment may include steroid creams, vitamin D3 cream, UV light, and immunosuppressants.
Global psoriasis treatment market is driven by increase in smoking and alcohol consumption trends globally. Increased spending on medicines and escalating health care expenditure are the key growth drivers of the market. Psoriasis treatment mainly treated by topical agents only. The Recent launch of systemic products into the market expected to drive the growth of the market. However, high cost of the drugs and side-effects associated with the existing medication for psoriasis are expected to hinder the psoriasis treatment market during the forecast period.
Psoriasis treatment market segmented on the basis of drug class, type, route of administration, and distribution channel
Based on drug class, global psoriasis treatment market is segmented into
Geographically, psoriasis treatment market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America accounts largest market in the psoriasis treatment market due to high prevalence of the disease. According to American Academy of Dermatology, approximately 7.5 Mn people in the United States have psoriasis. In Europe, the psoriasis treatment market is expected to grow at significant rate due to factors such as increased prevalence and growing awareness about skin diseases and recent launch of biosimilars such as elerzi, amzevita. In Asia-Pacific region, India and China are expected to be fastest growing market due to developing infrastructure and rapid growth in awareness and available treatment options for psoriasis.
Some of the market players in psoriasis treatment market include Amgen Inc. (U.S), Eli Lilly and Company(U.S), Novartis AG (Switzerland), Merck & Co., Inc. (U.S), Johnson & Johnson Services, Inc., (U.S) Pfizer, Inc. (U.S), AstraZeneca (U.K), AbbVie Inc. (U.S), LEO Pharma A/S (Denmark) and Biogen (U.S) to name a few.
In July 2017, Janssen Biotech, Inc.’s tremfya (guselkumab) approved by U.S. Food and Drug Administration (FDA) for the treatment of adults living with moderate to severe plaque psoriasis
In February 2017, US Food and Drug Administration (FDA) approved siliq(brodalumab) injection for the treatment of adult patients with moderate-to-severe plaque psoriasis. This drug was developed by Valeant Pharmaceuticals by partnering with AstraZeneca
REPORT OUTLINE:
Global psoriasis treatment market is driven by increase in smoking and alcohol consumption trends globally. Increased spending on medicines and escalating health care expenditure are the key growth drivers of the market. Psoriasis treatment mainly treated by topical agents only. The Recent launch of systemic products into the market expected to drive the growth of the market. However, high cost of the drugs and side-effects associated with the existing medication for psoriasis are expected to hinder the psoriasis treatment market during the forecast period.
Psoriasis treatment market segmented on the basis of drug class, type, route of administration, and distribution channel
Based on drug class, global psoriasis treatment market is segmented into
- TNF Inhibitors
- Vitamin D Analogues
- Interleukin Blockers
- Topical Corticosteroids
- Monoclonal Antibodies
- Others
- Plaque Psoriasis
- Guttate Psoriasis
- Flexural Psoriasis
- Inverse Psoriasis
- Psoriatic Psoriasis
- Oral
- Topical
- Parenteral
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Geographically, psoriasis treatment market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America accounts largest market in the psoriasis treatment market due to high prevalence of the disease. According to American Academy of Dermatology, approximately 7.5 Mn people in the United States have psoriasis. In Europe, the psoriasis treatment market is expected to grow at significant rate due to factors such as increased prevalence and growing awareness about skin diseases and recent launch of biosimilars such as elerzi, amzevita. In Asia-Pacific region, India and China are expected to be fastest growing market due to developing infrastructure and rapid growth in awareness and available treatment options for psoriasis.
Some of the market players in psoriasis treatment market include Amgen Inc. (U.S), Eli Lilly and Company(U.S), Novartis AG (Switzerland), Merck & Co., Inc. (U.S), Johnson & Johnson Services, Inc., (U.S) Pfizer, Inc. (U.S), AstraZeneca (U.K), AbbVie Inc. (U.S), LEO Pharma A/S (Denmark) and Biogen (U.S) to name a few.
In July 2017, Janssen Biotech, Inc.’s tremfya (guselkumab) approved by U.S. Food and Drug Administration (FDA) for the treatment of adults living with moderate to severe plaque psoriasis
In February 2017, US Food and Drug Administration (FDA) approved siliq(brodalumab) injection for the treatment of adult patients with moderate-to-severe plaque psoriasis. This drug was developed by Valeant Pharmaceuticals by partnering with AstraZeneca
REPORT OUTLINE:
- The report provides granular level information about the market size, regional market share and forecast from 2017-2023
- The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
- The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
- The report tracks recent innovations, key developments and startup’s details that are working in the industry
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
1. EXECUTIVE SUMMARY
2. GLOBAL PSORIASIS TREATMENT MARKET INTRODUCTION
2.1. Global Psoriasis Treatment Market– Taxonomy
2.2. Global Psoriasis Treatment Market–Definitions
2.2.1. Drug Class
2.2.2. Psoriasis Type
3. GLOBAL PSORIASIS TREATMENT MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Psoriasis Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Psoriasis Treatment Market– Recent Market Introductions
4. GLOBAL PSORIASIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL PSORIASIS TREATMENT MARKET FORECAST, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. TNF Inhibitors
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Vitamin D Analogues
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Interleukin Blockers
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Topical Corticosteroids
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Monoclonal Antibodies
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. GLOBAL PSORIASIS TREATMENT MARKET FORECAST, BY PSORIASIS TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Plaque Psoriasis
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Guttate Psoriasis
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Flexural Psoriasis
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Inverse Psoriasis
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Psoriatic Psoriasis
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. GLOBAL PSORIASIS TREATMENT MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Oral
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Topical
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Pareneteral
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL PSORIASIS TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9. GLOBAL PSORIASIS TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. North America
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Psoriasis Treatment Market- Opportunity Analysis Index - By Psoriasis Type, By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2017 – 2023
10. NORTH AMERICA PSORIASIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.1.1. TNF Inhibitors
10.1.1.2. Vitamin D Analogues
10.1.1.3. Interleukin Blockers
10.1.1.4. Topical Corticosteroids
10.1.1.5. Monoclonal Antibodies
10.1.1.6. Others
10.1.2. Psoriasis Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Plaque Psoriasis
10.1.2.2. Guttate Psoriasis
10.1.2.3. Flexural Psoriasis
10.1.2.4. Inverse Psoriasis
10.1.2.5. Psoriatic Psoriasis
10.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Oral
10.1.3.2. Topical
10.1.3.3. Parenteral
10.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Hospital Pharmacies
10.1.4.2. Retail Pharmacies
10.1.4.3. Online Pharmacies
10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.1.5.1. U.S.
10.1.5.2. Canada
10.1.6. North America Psoriasis Treatment Market- Opportunity Analysis Index - By Psoriasis Type, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
10.1.7. North America Psoriasis Treatment Market Dynamics – Trends
11. EUROPE PSORIASIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.1.1. TNF Inhibitors
11.1.1.2. Vitamin D Analogues
11.1.1.3. Interleukin Blockers
11.1.1.4. Topical Corticosteroids
11.1.1.5. Monoclonal Antibodies
11.1.1.6. Others
11.1.2. Psoriasis Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Plaque Psoriasis
11.1.2.2. Guttate Psoriasis
11.1.2.3. Flexural Psoriasis
11.1.2.4. Inverse Psoriasis
11.1.2.5. Psoriatic Psoriasis
11.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Oral
11.1.3.2. Topical
11.1.3.3. Parenteral
11.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.4.1. Hospital Pharmacies
11.1.4.2. Retail Pharmacies
11.1.4.3. Online Pharmacies
11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.5.1. Germany
11.1.5.2. UK
11.1.5.3. France
11.1.5.4. Spain
11.1.5.5. Italy
11.1.5.6. Russia
11.1.5.7. Poland
11.1.5.8. Rest of Europe
11.1.6. Europe Psoriasis Treatment Market- Opportunity Analysis Index - By Psoriasis Type, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
11.1.7. Europe Psoriasis Treatment Market Dynamics – Trends
12. ASIA-PACIFIC PSORIASIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.1.1. TNF Inhibitors
12.1.1.2. Vitamin D Analogues
12.1.1.3. Interleukin Blockers
12.1.1.4. Topical Corticosteroids
12.1.1.5. Monoclonal Antibodies
12.1.1.6. Others
12.1.2. Psoriasis Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Plaque Psoriasis
12.1.2.2. Guttate Psoriasis
12.1.2.3. Flexural Psoriasis
12.1.2.4. Inverse Psoriasis
12.1.2.5. Psoriatic Psoriasis
12.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Oral
12.1.3.2. Topical
12.1.3.3. Parenteral
12.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Hospital Pharmacies
12.1.4.2. Retail Pharmacies
12.1.4.3. Online Pharmacies
12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
12.1.5.1. Japan
12.1.5.2. China
12.1.5.3. India
12.1.5.4. ASEAN
12.1.5.5. Australia & New Zealand
12.1.5.6. Rest of Asia-Pacific
12.1.6. Asia-Pacific Psoriasis Treatment Market- Opportunity Analysis Index - By Psoriasis Type, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
12.1.7. Asia-Pacific Psoriasis Treatment Market Dynamics – Trends
13. LATIN AMERICA PSORIASIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.1.1. TNF Inhibitors
13.1.1.2. Vitamin D Analogues
13.1.1.3. Interleukin Blockers
13.1.1.4. Topical Corticosteroids
13.1.1.5. Monoclonal Antibodies
13.1.1.6. Others
13.1.2. Psoriasis Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. Plaque Psoriasis
13.1.2.2. Guttate Psoriasis
13.1.2.3. Flexural Psoriasis
13.1.2.4. Inverse Psoriasis
13.1.2.5. Psoriatic Psoriasis
13.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Oral
13.1.3.2. Topical
13.1.3.3. Parenteral
13.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.4.1. Hospital Pharmacies
13.1.4.2. Retail Pharmacies
13.1.4.3. Online Pharmacies
13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.5.1. Brazil
13.1.5.2. Mexico
13.1.5.3. Argentina
13.1.5.4. Venezuela
13.1.5.5. Rest of Latin America
13.1.6. Latin America Psoriasis Treatment Market- Opportunity Analysis Index - By Psoriasis Type, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
13.1.7. Latin America Psoriasis Treatment Market Dynamics – Trends
14. MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
14.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.1.1.1. TNF Inhibitors
14.1.1.2. Vitamin D Analogues
14.1.1.3. Interleukin Blockers
14.1.1.4. Topical Corticosteroids
14.1.1.5. Monoclonal Antibodies
14.1.1.6. Others
14.1.2. Psoriasis Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.1.2.1. Plaque Psoriasis
14.1.2.2. Guttate Psoriasis
14.1.2.3. Flexural Psoriasis
14.1.2.4. Inverse Psoriasis
14.1.2.5. Psoriatic Psoriasis
14.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.1.3.1. Oral
14.1.3.2. Topical
14.1.3.3. Parenteral
14.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.1.4.1. Hospital Pharmacies
14.1.4.2. Retail Pharmacies
14.1.4.3. Online Pharmacies
14.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.5.1. Gulf Cooperation Council (GCC) Countries
14.1.5.2. Israel
14.1.5.3. South Africa
14.1.5.4. Rest of MEA
14.1.6. MEA Psoriasis Treatment Market- Opportunity Analysis Index - By Psoriasis Type, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
14.1.7. MEA Psoriasis Treatment Market Dynamics – Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Amgen Inc. (U.S)
15.2.2. Eli Lilly and Company(U.S)
15.2.3. Novartis AG (Switzerland)
15.2.4. Merck & Co., Inc. (U.S)
15.2.5. Johnson & Johnson Services, Inc., (U.S)
15.2.6. Pfizer, Inc. (U.S)
15.2.7. AstraZeneca (U.K)
15.2.8. AbbVie Inc. (U.S)
15.2.9. LEO Pharma A/S (Denmark)
15.2.10. Biogen (U.S)
16. RESEARCH METHODOLOGY
17. KEY ASSUMPTIONS AND ACRONYMS
2. GLOBAL PSORIASIS TREATMENT MARKET INTRODUCTION
2.1. Global Psoriasis Treatment Market– Taxonomy
2.2. Global Psoriasis Treatment Market–Definitions
2.2.1. Drug Class
2.2.2. Psoriasis Type
3. GLOBAL PSORIASIS TREATMENT MARKET DYNAMICS
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Global Psoriasis Treatment Market Dynamics – Factors Impact Analysis
3.6. Global Psoriasis Treatment Market– Recent Market Introductions
4. GLOBAL PSORIASIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 – 2023
4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Oppurtunity Analysis
5. GLOBAL PSORIASIS TREATMENT MARKET FORECAST, BY DRUG CLASS, 2012 - 2016 AND FORECAST, 2017 - 2023
5.1. TNF Inhibitors
5.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Vitamin D Analogues
5.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Interleukin Blockers
5.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Topical Corticosteroids
5.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Monoclonal Antibodies
5.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6. GLOBAL PSORIASIS TREATMENT MARKET FORECAST, BY PSORIASIS TYPE, 2012 - 2016 AND FORECAST, 2017 - 2023
6.1. Plaque Psoriasis
6.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Guttate Psoriasis
6.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
6.3. Flexural Psoriasis
6.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.3.3. Market Opportunity Analysis
6.4. Inverse Psoriasis
6.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.4.3. Market Opportunity Analysis
6.5. Psoriatic Psoriasis
6.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
6.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.5.3. Market Opportunity Analysis
7. GLOBAL PSORIASIS TREATMENT MARKET FORECAST, BY ROUTE OF ADMINISTRATION, 2012 - 2016 AND FORECAST, 2017 - 2023
7.1. Oral
7.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Topical
7.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Pareneteral
7.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8. GLOBAL PSORIASIS TREATMENT MARKET FORECAST, BY DISTRIBUTION CHANNEL, 2012 - 2016 AND FORECAST, 2017 - 2023
8.1. Hospital Pharmacies
8.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Retail Pharmacies
8.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Online Pharmacies
8.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
9. GLOBAL PSORIASIS TREATMENT MARKET FORECAST, BY REGION, 2012 - 2016 AND FORECAST, 2017 - 2023
9.1. North America
9.1.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.1.3. Market Opportunity Analysis
9.2. Europe
9.2.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.2.3. Market Opportunity Analysis
9.3. Asia-Pacific
9.3.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.3.3. Market Opportunity Analysis
9.4. Latin America
9.4.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.4.3. Market Opportunity Analysis
9.5. Middle East and Africa
9.5.1. Market Analysis, 2012 – 2016 and Forecast, 2017 – 2023 (Revenue, USD Mn)
9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
9.5.3. Market Opportunity Analysis
9.6. Global Psoriasis Treatment Market- Opportunity Analysis Index - By Psoriasis Type, By Drug Class, By Route of Administration, By Distribution Channel, and Region, 2017 – 2023
10. NORTH AMERICA PSORIASIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
10.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.1.1. TNF Inhibitors
10.1.1.2. Vitamin D Analogues
10.1.1.3. Interleukin Blockers
10.1.1.4. Topical Corticosteroids
10.1.1.5. Monoclonal Antibodies
10.1.1.6. Others
10.1.2. Psoriasis Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.2.1. Plaque Psoriasis
10.1.2.2. Guttate Psoriasis
10.1.2.3. Flexural Psoriasis
10.1.2.4. Inverse Psoriasis
10.1.2.5. Psoriatic Psoriasis
10.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.3.1. Oral
10.1.3.2. Topical
10.1.3.3. Parenteral
10.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
10.1.4.1. Hospital Pharmacies
10.1.4.2. Retail Pharmacies
10.1.4.3. Online Pharmacies
10.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
10.1.5.1. U.S.
10.1.5.2. Canada
10.1.6. North America Psoriasis Treatment Market- Opportunity Analysis Index - By Psoriasis Type, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
10.1.7. North America Psoriasis Treatment Market Dynamics – Trends
11. EUROPE PSORIASIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
11.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.1.1. TNF Inhibitors
11.1.1.2. Vitamin D Analogues
11.1.1.3. Interleukin Blockers
11.1.1.4. Topical Corticosteroids
11.1.1.5. Monoclonal Antibodies
11.1.1.6. Others
11.1.2. Psoriasis Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.2.1. Plaque Psoriasis
11.1.2.2. Guttate Psoriasis
11.1.2.3. Flexural Psoriasis
11.1.2.4. Inverse Psoriasis
11.1.2.5. Psoriatic Psoriasis
11.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.3.1. Oral
11.1.3.2. Topical
11.1.3.3. Parenteral
11.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.4.1. Hospital Pharmacies
11.1.4.2. Retail Pharmacies
11.1.4.3. Online Pharmacies
11.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
11.1.5.1. Germany
11.1.5.2. UK
11.1.5.3. France
11.1.5.4. Spain
11.1.5.5. Italy
11.1.5.6. Russia
11.1.5.7. Poland
11.1.5.8. Rest of Europe
11.1.6. Europe Psoriasis Treatment Market- Opportunity Analysis Index - By Psoriasis Type, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
11.1.7. Europe Psoriasis Treatment Market Dynamics – Trends
12. ASIA-PACIFIC PSORIASIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
12.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.1.1. TNF Inhibitors
12.1.1.2. Vitamin D Analogues
12.1.1.3. Interleukin Blockers
12.1.1.4. Topical Corticosteroids
12.1.1.5. Monoclonal Antibodies
12.1.1.6. Others
12.1.2. Psoriasis Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.2.1. Plaque Psoriasis
12.1.2.2. Guttate Psoriasis
12.1.2.3. Flexural Psoriasis
12.1.2.4. Inverse Psoriasis
12.1.2.5. Psoriatic Psoriasis
12.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.3.1. Oral
12.1.3.2. Topical
12.1.3.3. Parenteral
12.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
12.1.4.1. Hospital Pharmacies
12.1.4.2. Retail Pharmacies
12.1.4.3. Online Pharmacies
12.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn),
Y-o-Y Growth (%), and Market Share (%)
12.1.5.1. Japan
12.1.5.2. China
12.1.5.3. India
12.1.5.4. ASEAN
12.1.5.5. Australia & New Zealand
12.1.5.6. Rest of Asia-Pacific
12.1.6. Asia-Pacific Psoriasis Treatment Market- Opportunity Analysis Index - By Psoriasis Type, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
12.1.7. Asia-Pacific Psoriasis Treatment Market Dynamics – Trends
13. LATIN AMERICA PSORIASIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
13.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.1.1. TNF Inhibitors
13.1.1.2. Vitamin D Analogues
13.1.1.3. Interleukin Blockers
13.1.1.4. Topical Corticosteroids
13.1.1.5. Monoclonal Antibodies
13.1.1.6. Others
13.1.2. Psoriasis Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.2.1. Plaque Psoriasis
13.1.2.2. Guttate Psoriasis
13.1.2.3. Flexural Psoriasis
13.1.2.4. Inverse Psoriasis
13.1.2.5. Psoriatic Psoriasis
13.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.3.1. Oral
13.1.3.2. Topical
13.1.3.3. Parenteral
13.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.4.1. Hospital Pharmacies
13.1.4.2. Retail Pharmacies
13.1.4.3. Online Pharmacies
13.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
13.1.5.1. Brazil
13.1.5.2. Mexico
13.1.5.3. Argentina
13.1.5.4. Venezuela
13.1.5.5. Rest of Latin America
13.1.6. Latin America Psoriasis Treatment Market- Opportunity Analysis Index - By Psoriasis Type, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
13.1.7. Latin America Psoriasis Treatment Market Dynamics – Trends
14. MIDDLE EAST & AFRICA PSORIASIS TREATMENT MARKET ANALYSIS, 2012 - 2016 AND FORECAST, 2017 - 2023
14.1.1. Drug Class Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.1.1.1. TNF Inhibitors
14.1.1.2. Vitamin D Analogues
14.1.1.3. Interleukin Blockers
14.1.1.4. Topical Corticosteroids
14.1.1.5. Monoclonal Antibodies
14.1.1.6. Others
14.1.2. Psoriasis Type Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.1.2.1. Plaque Psoriasis
14.1.2.2. Guttate Psoriasis
14.1.2.3. Flexural Psoriasis
14.1.2.4. Inverse Psoriasis
14.1.2.5. Psoriatic Psoriasis
14.1.3. Route of Administration Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.1.3.1. Oral
14.1.3.2. Topical
14.1.3.3. Parenteral
14.1.4. Distribution Channel Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
14.1.4.1. Hospital Pharmacies
14.1.4.2. Retail Pharmacies
14.1.4.3. Online Pharmacies
14.1.5. Country Analysis (2012 – 2016) and Forecast (2017 – 2023) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
14.1.5.1. Gulf Cooperation Council (GCC) Countries
14.1.5.2. Israel
14.1.5.3. South Africa
14.1.5.4. Rest of MEA
14.1.6. MEA Psoriasis Treatment Market- Opportunity Analysis Index - By Psoriasis Type, By Drug Class, By Route of Administration, By Distribution Channel, and Country, 2017 – 2023
14.1.7. MEA Psoriasis Treatment Market Dynamics – Trends
15. COMPETITION LANDSCAPE
15.1. Strategic Dashboard of Top Market Players
15.2. Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
15.2.1. Amgen Inc. (U.S)
15.2.2. Eli Lilly and Company(U.S)
15.2.3. Novartis AG (Switzerland)
15.2.4. Merck & Co., Inc. (U.S)
15.2.5. Johnson & Johnson Services, Inc., (U.S)
15.2.6. Pfizer, Inc. (U.S)
15.2.7. AstraZeneca (U.K)
15.2.8. AbbVie Inc. (U.S)
15.2.9. LEO Pharma A/S (Denmark)
15.2.10. Biogen (U.S)
16. RESEARCH METHODOLOGY
17. KEY ASSUMPTIONS AND ACRONYMS